{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:37:04Z","timestamp":1793147824306,"version":"4.5.0"},"reference-count":143,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Solid organ transplant recipients (SOTRs) are highly vulnerable to severe COVID-19 infection, yet initial vaccine trials provided limited data on efficacy and safety in this immunocompromised population. Heterogeneous seroconversion rates and conflicting safety reports complicate the formulation of clear clinical guidelines. This systematic review and meta-analysis aim to aggregate existing evidence to determine the precise seroconversion and safety profiles of COVID-19 vaccines and identify key factors influencing immune response in SOTRs. Methods: A comprehensive literature search was conducted identifying 125 studies evaluating WHO\/FDA-authorized vaccines in SOTRs. Outcomes were the pooled seroconversion proportion and safety profile. Subgroup analyses were performed based on vaccine type, transplanted organ, number of doses, and prior SARS-CoV-2 infection status, confirmed by leave-one-out sensitivity analysis and bootstrap methods. Results: Most studies assessed mRNA-based vaccines (123\/125, 98.4%). The overall pooled seroconversion proportion across all SOTRs was significantly blunted at 0.49 (95% CI, 0.43 to 0.55), demonstrating high heterogeneity (I2 = 94.2%). Seroconversion showed a clear positive dose\u2013response relationship, increasing from 27% after one dose to 84% after four doses. Prior COVID-19 infection was the strongest predictor of a response, resulting in a pooled seroconversion of 0.90 (95% CI, 0.82 to 0.94; I2 = 0%). Organ-specific analyses revealed the highest response in Liver recipients (0.80) and the lowest in Lung recipients (0.29). Vaccine platform analysis showed that the highest response was with mRNA-1273 (0.55) and the lowest with CoronaVac (0.29). The safety profile was limited. Conclusions: SOTRs exhibit profound hypo responsiveness to COVID-19 vaccines; however, the extreme heterogeneity observed across studies necessitates a cautious interpretation of pooled seroconversion estimates. While the data indicates a significant dose\u2013response relationship favoring an aggressive, multi-dose strategy, the apparent safety profile may reflect under-reporting and limited follow-up rather than confirmed safety equivalence. Rare but clinically critical outcomes, such as acute allograft rejection, remain inadequately characterized in the current literature. Consequently, while the prioritization of multi-dose regimens and hybrid immunity is supported to maximize protection, clinicians must recognize that individual responses remain highly variable, and the long-term immunological impact of repeated stimulation requires further standardized investigation.<\/jats:p>","DOI":"10.3390\/vaccines14010072","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:56:55Z","timestamp":1767877015000},"page":"72","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of mRNA-Based COVID-19 Vaccines in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"14","author":[{"given":"Maya","family":"Alkhidir","sequence":"first","affiliation":[{"name":"College of Medicine & Health Sciences, Arabian Gulf University, Manama 26671, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3811-6503","authenticated-orcid":false,"given":"Kannan","family":"Sridharan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Therapeutics, College of Medicine & Health Sciences, Arabian Gulf University, Manama 26671, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/14760584.2022.2042257","article-title":"Clinical development and approval of COVID-19 vaccines","volume":"21","author":"Kalinke","year":"2022","journal-title":"Expert Rev. Vaccines"},{"key":"ref_2","unstructured":"World Health Organization (2025, September 09). Global COVID-19 Overview|Who COVID-19 Dashboard [Internet]. Available online: https:\/\/data.who.int\/dashboards\/covid19\/summary."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"26331055231180543","DOI":"10.1177\/26331055231180543","article-title":"COVID-19 vaccine evolution and beyond","volume":"18","author":"Brice","year":"2023","journal-title":"Neurosci. Insights"},{"key":"ref_4","unstructured":"U.S. National Library of Medicine (2025, December 15). Immunocompromised Host [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/mesh?Db=mesh&Cmd=DetailsSearch&Term=%22Immunocompromised%2BHost%22%5BMeSH%2BTerms%5D."},{"key":"ref_5","first-page":"10","article-title":"Predictors of disease severity and outcome of hospitalized renal transplant recipients with COVID-19 infection: A systematic review of a globally representative sample","volume":"59","author":"Hasan","year":"2021","journal-title":"Rom. J. Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e068632","DOI":"10.1136\/bmj-2021-068632","article-title":"Efficacy of COVID-19 vaccines in immunocompromised patients: Systematic review and meta-analysis","volume":"376","author":"Wong","year":"2022","journal-title":"BMJ"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Alotaibi, A.S., Shalabi, H.A., Alhifany, A.A., Alotaibi, N.E., Alnuhait, M.A., Altheaby, A.R., and Alhazmi, A.Y. (2023). Humoral and cellular immunity following five doses of COVID-19 vaccines in solid organ transplant recipients: A systematic review and meta-analysis. Vaccines, 11.","DOI":"10.3390\/vaccines11071166"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/TP.0000000000004386","article-title":"Humoral and cellular response of transplant recipients to a third dose of mrna SARS-CoV-2 vaccine: A systematic review and meta-analysis","volume":"107","author":"Bailey","year":"2022","journal-title":"Transplantation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e226822","DOI":"10.1001\/jamanetworkopen.2022.6822","article-title":"Immunogenicity and risk factors associated with poor humoral immune response of SARS-CoV-2 vaccines in recipients of solid organ transplant","volume":"5","author":"Manothummetha","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Mu, Y., Wu, H., Jiang, Z., Liu, K., Xue, X., Zhang, W., and Chen, Z. (2023). Serological responses after a fourth dose of SARS-CoV-2 vaccine in solid organ transplant recipients: A systematic review and meta-analysis. Vaccines, 11.","DOI":"10.3390\/vaccines11071130"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/ndt\/gfac174","article-title":"Seroconversion rate after primary vaccination with two doses of BNT162B2 versus mRNA-1273 in solid organ transplant recipients: A systematic review and meta-analysis","volume":"37","author":"Verleye","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cmi.2022.12.004","article-title":"Immunogenicity of COVID-19 vaccines in solid organ transplant recipients: A systematic review and meta-analysis","volume":"29","author":"Chen","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5849","DOI":"10.7150\/ijbs.77030","article-title":"Humoral immunogenicity to SARS-CoV-2 vaccination in liver transplant recipients: A systematic review and meta-analysis","volume":"18","author":"Yoo","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"ref_14","unstructured":"(2025, December 15). Systematic Review of COVID Vaccines in Patients with Altered Immune Status. Prtocol. Available online: https:\/\/osf.io\/zh8q7\/files\/768tb."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13643-016-0259-8","article-title":"Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: Overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews","volume":"5","author":"Laursen","year":"2016","journal-title":"Syst. Rev."},{"key":"ref_16","first-page":"2127","article-title":"Methodological quality of case series studies: An introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid. Synth."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Rashidi-Alavijeh, J., Frey, A., Passenberg, M., Korth, J., Zmudzinski, J., Anastasiou, O.E., Saner, F.H., Jahn, M., Lange, C.M., and Willuweit, K. (2021). Humoral Response to SARS-CoV-2 Vaccination in Liver Transplant Recipients\u2013A Single-Center Experience. Vaccines, 9.","DOI":"10.3390\/vaccines9070738"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"eabj1031","DOI":"10.1126\/sciimmunol.abj1031","article-title":"Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients","volume":"6","author":"Choi","year":"2021","journal-title":"Sci. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/clinchem\/hvab149","article-title":"Poor Humoral Response in Solid Organ Transplant Recipients Following Complete mRNA SARS-CoV-2 Vaccination","volume":"68","author":"Cao","year":"2021","journal-title":"Clin. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Balsby, D., Nilsson, A.C., Petersen, I., Lindvig, S.O., Davidsen, J.R., Abazi, R., Poulsen, M.K., Holden, I.K., Justesen, U.S., and Bistrup, C. (2022). Humoral immune response following a third SARS-CoV-2 mRNA vaccine dose in solid organ transplant recipients compared with matched controls. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1039245"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1097\/TP.0000000000003999","article-title":"BNT162B2 mRNA COVID-19 Vaccine in Heart and Lung Transplanted Young Adults: Is an Alternative SARS-CoV-2 Immune Response Surveillance Needed?","volume":"106","author":"Cotugno","year":"2021","journal-title":"Transplantation"},{"key":"ref_22","first-page":"322","article-title":"Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients","volume":"22","author":"Abravanel","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1097\/TP.0000000000003892","article-title":"T-cell and Antibody Response After 2 Doses of the BNT162b2 Vaccine in a Belgian Cohort of Kidney Transplant Recipients","volume":"105","author":"Devresse","year":"2021","journal-title":"Transplantation"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1111\/ajt.16726","article-title":"Serological response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients depends on prior exposure to SARS-CoV-2","volume":"21","author":"Firket","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1097\/TP.0000000000003861","article-title":"Disappointing Immunization Rate After 2 Doses of the BNT162b2 Vaccine in a Belgian Cohort of Kidney Transplant Recipients","volume":"105","author":"Georgery","year":"2021","journal-title":"Transplantation"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Havlin, J., Skotnicova, A., Dvorackova, E., Hubacek, P., Svorcova, M., Lastovicka, J., Sediva, A., Kalina, T., and Lischke, R. (2021). Impaired Humoral Response to Third Dose of BNT162b2 mRNA COVID-19 Vaccine Despite Detectable Spike Protein\u2013specific T cells in Lung Transplant Recipients. Transplantation, Publish Ahead of Print.","DOI":"10.1097\/TP.0000000000004021"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Hoffman, T.W., Meek, B., Rijkers, G.T., and van Kessel, D.A. (2021). Poor Serologic Response to Two Doses of an mRNA-Based SARS-CoV-2 Vaccine in Lung Transplant Recipients. Transplantation, Publish Ahead of Print.","DOI":"10.1016\/j.trim.2022.101599"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/joim.13361","article-title":"Immunogenicity of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients","volume":"290","author":"Holden","year":"2021","journal-title":"J. Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.ekir.2021.04.017","article-title":"Postvaccine Anti\u2013SARS-CoV-2 Spike Protein Antibody Development in Kidney Transplant Recipients","volume":"6","author":"Husain","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1111\/ajt.16814","article-title":"Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept","volume":"21","author":"Chavarot","year":"2021","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1097\/TP.0000000000003784","article-title":"Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated with Belatacept","volume":"105","author":"Chavarot","year":"2021","journal-title":"Transplantation"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Chukwu, C.A., Mahmood, K., Elmakki, S., Gorton, J., Kalra, P.A., Poulikakos, D., and Middleton, R. (2022). Evaluating the antibody response to SARS-CoV-2 vaccination amongst kidney transplant recipients at a single nephrology centre. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0265130"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00467-021-05256-9","article-title":"Immunologic response of mRNA SARS-CoV-2 vaccination in adolescent kidney transplant recipients","volume":"37","author":"Crane","year":"2021","journal-title":"Pediatr. Nephrol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Noble, J., Langello, A., Bouchut, W., Lupo, J., Lombardo, D., and Rostaing, L. (2021). Immune Response Post-SARS-CoV-2 mRNA Vaccination in Kidney-Transplant Recipients Receiving Belatacept. Transplantation, Publish Ahead of Print.","DOI":"10.1097\/TP.0000000000003923"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.kint.2021.09.006","article-title":"The SARS-CoV-2\u2013neutralizing capacity of kidney transplant recipients 4 weeks after receiving a second dose of the BNT162b2 vaccine","volume":"100","author":"Pedersen","year":"2021","journal-title":"Kidney Int."},{"key":"ref_36","first-page":"e95","article-title":"Clinical Impact, Reactogenicity, and Immunogenicity After the First CoronaVac Dose in Kidney Transplant Recipients","volume":"106","author":"Cristelli","year":"2021","journal-title":"Transplantation"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2213-2600(21)00184-3","article-title":"Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine","volume":"9","author":"Shostak","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/ajt.16829","article-title":"Protecting kidney transplant recipients against SARS-CoV-2 infection: A third dose of vaccine is necessary now","volume":"22","author":"Villanego","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1111\/ajt.17054","article-title":"Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients","volume":"22","author":"Benning","year":"2022","journal-title":"Am. J. Transplant."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1093\/ckj\/sfab100","article-title":"Antibody response to SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients and in-centre and satellite centre haemodialysis patients","volume":"14","author":"Bertrand","year":"2021","journal-title":"Clin. Kidney J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1097\/TP.0000000000003850","article-title":"Antibody Response to the Janssen COVID-19 Vaccine in Solid Organ Transplant Recipients","volume":"105","author":"Boyarsky","year":"2021","journal-title":"Transplantation"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00508-022-02103-1","article-title":"Humoral response after a third and fourth dose of mRNA-based SARS-CoV-2 vaccine in previously seronegative kidney transplant recipients","volume":"134","author":"Brandstetter","year":"2022","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1111\/ajt.17151","article-title":"An additional dose of viral vector COVID-19 vaccine and mRNA COVID-19 vaccine in kidney transplant recipients: A randomized controlled trial (CVIM 4 study)","volume":"22","author":"Bruminhent","year":"2022","journal-title":"Am. J. Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1111\/ajt.16701","article-title":"Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients","volume":"21","author":"Cucchiari","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"101158","DOI":"10.1016\/j.eclinm.2021.101158","article-title":"BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study","volume":"41","author":"Rahav","year":"2021","journal-title":"EClinicalMedicine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jhep.2021.04.020","article-title":"Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients","volume":"75","author":"Rabinowich","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1681\/ASN.2021040490","article-title":"Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients","volume":"32","author":"Danthu","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40620-021-01210-y","article-title":"Impact of tozinameran (BNT162b2) mRNA vaccine on kidney transplant and chronic dialysis patients: 3\u20135 months follow-up","volume":"35","author":"Oster","year":"2022","journal-title":"J. Nephrol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e794","DOI":"10.1097\/TXD.0000000000001246","article-title":"Discordance Between SARS-CoV-2\u2013specific Cell-mediated and Antibody Responses Elicited by mRNA-1273 Vaccine in Kidney and Liver Transplant Recipients","volume":"7","author":"Carretero","year":"2021","journal-title":"Transplant. Direct"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e1397","DOI":"10.1097\/TXD.0000000000001397","article-title":"Predictors of Nonseroconversion to SARS-CoV-2 Vaccination in Kidney Transplant Recipients","volume":"8","author":"Bouwmans","year":"2022","journal-title":"Transplant. Direct"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1111\/ajt.16615","article-title":"Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus","volume":"21","author":"Grupper","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.cgh.2022.01.012","article-title":"Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients","volume":"20","author":"Guarino","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1111\/ajt.16766","article-title":"Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients","volume":"21","author":"Hall","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.healun.2021.07.026","article-title":"SARS-CoV-2 messenger RNA vaccine antibody response and reactogenicity in heart and lung transplant recipients","volume":"40","author":"Hallett","year":"2021","journal-title":"J. Heart Lung Transplant."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Hamm, S.R., M\u00f8ller, D.L., P\u00e9rez-Al\u00f3s, L., Hansen, C.B., Pries-Heje, M.M., Heftdal, L.D., Hasselbalch, R.B., Fogh, K., Madsen, J.R., and Almagro Armenteros, J.J. (2022). Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.832501"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.healun.2021.05.004","article-title":"Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine and SARS-CoV-2 Infection in Lung Transplant Recipients","volume":"40","author":"Havlin","year":"2021","journal-title":"J. Heart Lung Transplant."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Heinzel, A., Schrezenmeier, E., Regele, F., Hu, K., Raab, L., Eder, M., Aigner, C., Jabbour, R., Aschauer, C., and Stefanski, A.L. (2022). Three-Month Follow-Up of Heterologous vs. Homologous Third SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Secondary Analysis of a Randomized Controlled Trial. Front. Med., 9.","DOI":"10.3389\/fmed.2022.936126"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1111\/ajt.16768","article-title":"Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients","volume":"21","author":"Herrera","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Hod, T., Ben-David, A., Olmer, L., Levy, I., Ghinea, R., Mor, E., Lustig, Y., and Rahav, G. (2021). Humoral Response of Renal Transplant Recipients to the BNT162b2 SARS-CoV-2 mRNA Vaccine Using Both RBD IgG and Neutralizing Antibodies. Transplantation, Publish Ahead of Print.","DOI":"10.1097\/TP.0000000000003889"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1097\/TP.0000000000004140","article-title":"A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients with Suboptimal Vaccine Response","volume":"106","author":"Karaba","year":"2022","journal-title":"Transplantation"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.cgh.2021.09.003","article-title":"SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients","volume":"20","author":"Ruether","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/TP.0000000000003983","article-title":"The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients with Chronic Kidney Disease, on Dialysis, or Living with a Kidney Transplant","volume":"106","author":"Sanders","year":"2021","journal-title":"Transplantation"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1111\/ajt.16818","article-title":"Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients","volume":"21","author":"Schmidt","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1681\/ASN.2021070966","article-title":"B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients","volume":"32","author":"Schrezenmeier","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/ckj\/sfab291","article-title":"Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant","volume":"15","author":"Seija","year":"2021","journal-title":"Clin. Kidney J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/TP.0000000000004383","article-title":"Humoral Response to the Fourth BNT162b2 Vaccination and Link Between the Fourth Dose, Omicron Infection, and Disease Severity in Renal Transplant Recipients","volume":"107","author":"Hod","year":"2022","journal-title":"Transplantation"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"D\u0119bska-\u015alizie\u0144, A., \u015alizie\u0144, Z., Muchlado, M., Kubanek, A., Piotrowska, M., D\u0105browska, M., Tarasewicz, A., Chamienia, A., Biedunkiewicz, B., and Renke, M. (2021). Predictors of Humoral Response to mRNA COVID19 Vaccines in Kidney Transplant Recipients: A Longitudinal Study\u2014The COViNEPH Project. Vaccines, 9.","DOI":"10.3390\/vaccines9101165"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1111\/ajt.16607","article-title":"Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients","volume":"21","author":"Marinaki","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/ndt\/gfab352","article-title":"mRNA-1273 vaccine (Moderna): A better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients?","volume":"37","author":"Wijtvliet","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1097\/TP.0000000000003764","article-title":"Kidney Transplant Recipients Rarely Show an Early Antibody Response Following the First COVID-19 Vaccine Administration","volume":"105","author":"Yi","year":"2021","journal-title":"Transplantation"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/ejhf.2199","article-title":"Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients\u2014A prospective cohort study","volume":"23","author":"Shaul","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1173.e1","DOI":"10.1016\/j.cmi.2021.04.028","article-title":"Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: A prospective cohort study","volume":"27","author":"Yahav","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Vaiciuniene, R., Sitkauskiene, B., Bumblyte, I.A., Dalinkeviciene, E., Ziginskiene, E., Bagdonas, D., Augliene, R., Petruliene, K., Bagdziuniene, I., and Skarupskiene, I. (2021). Immune Response after SARS-CoV-2 Vaccination in Kidney Transplant Patients. Medicina, 57.","DOI":"10.3390\/medicina57121327"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Tylicki, L., D\u0119bska-\u015alizie\u0144, A., Muchlado, M., \u015alizie\u0144, Z., Go\u0142\u0119biewska, J., D\u0105browska, M., and Biedunkiewicz, B. (2021). Boosting Humoral Immunity from mRNA COVID-19 Vaccines in Kidney Transplant Recipients. Vaccines, 10.","DOI":"10.3390\/vaccines10010056"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Tsoutsoura, P., Xagas, E., Roussos, S., Hatzakis, A., Gourzi, P., Boletis, I.N., and Marinaki, S. (2023). Assessment of mRNA Vaccine Immunogenicity in Solid Organ Transplant Recipients. Medicina, 59.","DOI":"10.3390\/medicina59061075"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Timmermann, L., Globke, B., Lurje, G., Schmelzle, M., Sch\u00f6ning, W., \u00d6llinger, R., Pratschke, J., Ebersp\u00e4cher, B., Drosten, C., and Hofmann, J. (2021). Humoral Immune Response following SARS-CoV-2 Vaccination in Liver Transplant Recipients. Vaccines, 9.","DOI":"10.3390\/vaccines9121422"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jhep.2021.08.008","article-title":"Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases","volume":"75","author":"Thuluvath","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"101642","DOI":"10.1016\/j.eclinm.2022.101642","article-title":"Immune responses following 3rd and 4th doses of heterologous and homologous COVID-19 vaccines in kidney transplant recipients","volume":"53","author":"Thomson","year":"2022","journal-title":"eClinicalMedicine"},{"key":"ref_79","first-page":"100178","article-title":"Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine","volume":"9","author":"Stumpf","year":"2021","journal-title":"Lancet Reg. Health\u2013Eur."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1097\/TP.0000000000003903","article-title":"Cellular and Humoral Immune Responses After 3 Doses of BNT162b2 mRNA SARS-CoV-2 Vaccine in Kidney Transplant","volume":"105","author":"Stumpf","year":"2021","journal-title":"Transplantation"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jamainternmed.2021.7372","article-title":"Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients","volume":"182","author":"Heinzel","year":"2022","journal-title":"JAMA Intern. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e157836","DOI":"10.1172\/jci.insight.157836","article-title":"Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination\u2013specific humoral and cellular immunity in kidney transplant recipients","volume":"7","author":"Schrezenmeier","year":"2022","journal-title":"JCI Insight"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1007\/s00392-021-01880-5","article-title":"Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients","volume":"110","author":"Schramm","year":"2021","journal-title":"Clin. Res. Cardiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e14495","DOI":"10.1111\/ctr.14495","article-title":"SARS-CoV-2 vaccination with BNT162B2 in renal transplant patients: Risk factors for impaired response and immunological implications","volume":"36","author":"Russo","year":"2021","journal-title":"Clin. Transplant."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1093\/ndt\/gfab313","article-title":"Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: The SENCOVAC study","volume":"37","author":"Quiroga","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.healun.2021.08.010","article-title":"Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience","volume":"41","author":"Peled","year":"2022","journal-title":"J. Heart Lung Transplant."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1097\/TP.0000000000003824","article-title":"Immunogenicity and Reactogenicity After SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Taking Belatacept","volume":"105","author":"Ou","year":"2021","journal-title":"Transplantation"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Osmanodja, B., Ronicke, S., Budde, K., Jens, A., Hammett, C., Koch, N., Seelow, E., Waiser, J., Zukunft, B., and Bachmann, F. (2022). Serological Response to Three, Four and Five Doses of SARS-CoV-2 Vaccine in Kidney Transplant Recipients. J. Clin. Med., 11.","DOI":"10.1101\/2022.03.23.22270017"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/cid\/ciab580","article-title":"Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients","volume":"74","author":"Mazzola","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Buchwinkler, L., Solagna, C.A., Messner, J., Pirklbauer, M., Rudnicki, M., Mayer, G., and Kerschbaum, J. (2021). Antibody Response to mRNA Vaccines against SARS-CoV-2 with Chronic Kidney Disease, Hemodialysis, and after Kidney Transplantation. J. Clin. Med., 11.","DOI":"10.3390\/jcm11010148"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.kint.2021.03.014","article-title":"Weak anti\u2013SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients","volume":"99","author":"Benotmane","year":"2021","journal-title":"Kidney Int."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.kint.2021.04.005","article-title":"Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine","volume":"99","author":"Benotmane","year":"2021","journal-title":"Kidney Int."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/ajt.16854","article-title":"Negative immune responses to two-dose mRNA COVID-19 vaccines in renal allograft recipients assessed with simple antibody and interferon gamma release assay cellular monitoring","volume":"22","author":"Crespo","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1016\/j.cgh.2022.06.028","article-title":"Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients","volume":"20","author":"Harberts","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1097\/TP.0000000000003922","article-title":"Serological Response to the BNT162b2 COVID-19 mRNA Vaccine in Adolescent and Young Adult Kidney Transplant Recipients","volume":"105","author":"Haskin","year":"2021","journal-title":"Transplantation"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/ajt.16851","article-title":"Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients","volume":"22","author":"Kantauskaite","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1473-3099(22)00650-8","article-title":"Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): A randomised clinical trial","volume":"23","author":"Kho","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Korth, J., Jahn, M., Dorsch, O., Anastasiou, O.E., Sorge-H\u00e4dicke, B., Eisenberger, U., G\u00e4ckler, A., Dittmer, U., Witzke, O., and Wilde, B. (2021). Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech). Viruses, 13.","DOI":"10.3390\/v13050756"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/ajt.17020","article-title":"Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine","volume":"22","author":"Kumar","year":"2022","journal-title":"Am. J. Transplant."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Marlet, J., Gatault, P., Maakaroun, Z., Longuet, H., Stefic, K., Handala, L., Eymieux, S., Gyan, E., Dartigeas, C., and Gaudy-Graffin, C. (2021). Antibody Responses after a Third Dose of COVID-19 Vaccine in Kidney Transplant Recipients and Patients Treated for Chronic Lymphocytic Leukemia. Vaccines, 9.","DOI":"10.3390\/vaccines9101055"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.healun.2021.04.003","article-title":"BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response","volume":"40","author":"Peled","year":"2021","journal-title":"J. Heart Lung Transplant."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Narasimhan, M., Mahimainathan, L., E Clark, A., Usmani, A., Cao, J., Araj, E., Torres, F., Sarode, R., Kaza, V., and Lacelle, C. (2021). Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines. Vaccines, 9.","DOI":"10.1101\/2021.04.26.21255926"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"6404","DOI":"10.1016\/j.vaccine.2022.08.065","article-title":"SARS-CoV-2 anti-spike antibodies after a fourth dose of COVID-19 vaccine in adult solid-organ transplant recipients","volume":"40","author":"Perrier","year":"2022","journal-title":"Vaccine"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"103705","DOI":"10.1016\/j.ebiom.2021.103705","article-title":"Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial","volume":"74","author":"Bergman","year":"2021","journal-title":"EBioMedicine"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.kint.2021.11.024","article-title":"Observations on improving COVID-19 vaccination responses in kidney transplant recipients: Heterologous vaccination and immunosuppression modulation","volume":"101","author":"Masset","year":"2022","journal-title":"Kidney Int."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"103679","DOI":"10.1016\/j.ebiom.2021.103679","article-title":"Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients","volume":"73","author":"Massa","year":"2021","journal-title":"EBioMedicine"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.kint.2021.08.019","article-title":"Risk factors associated with poor response to COVID-19 vaccination in kidney transplant recipients","volume":"100","author":"Azzi","year":"2021","journal-title":"Kidney Int."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jama.2021.12339","article-title":"Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients with Minimal Serologic Response to 2 Doses","volume":"326","author":"Benotmane","year":"2021","journal-title":"JAMA"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1681\/ASN.2021040480","article-title":"Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients","volume":"32","author":"Bertrand","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.kint.2021.09.014","article-title":"Antibody and T cell response to a third dose of SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients","volume":"100","author":"Bertrand","year":"2021","journal-title":"Kidney Int."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/lt.26351","article-title":"Clinical Factors Associated with Lack of Serological Response to SARS-CoV-2 Messenger RNA Vaccine in Liver Transplantation Recipients","volume":"28","author":"Cholankeril","year":"2021","journal-title":"Liver Transplant."},{"key":"ref_112","first-page":"180","article-title":"Coordinated cellular and humoral immune responses after two-dose SARS-CoV2 mRNA vaccination in liver transplant recipients","volume":"42","author":"Agrati","year":"2021","journal-title":"Liver Int."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/lt.26366","article-title":"Immunogenicity and Adverse Effect of Two Dose BNT162b2 mRNA Vaccine Among Liver Transplant Recipients","volume":"28","author":"Davidov","year":"2021","journal-title":"Liver Transplant."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1056\/NEJMc2111462","article-title":"Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients","volume":"385","author":"Hall","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1056\/NEJMc2108861","article-title":"Three Doses of an mRNA COVID-19 Vaccine in Solid-Organ Transplant Recipients","volume":"385","author":"Kamar","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.7326\/M21-1341","article-title":"Safety and Immunogenicity of Anti\u2013SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants","volume":"174","author":"Marion","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.kint.2021.08.017","article-title":"A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response","volume":"100","author":"Masset","year":"2021","journal-title":"Kidney Int."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.kint.2021.09.001","article-title":"A third vaccine dose substantially improves humoral and cellular SARS-CoV-2 immunity in renal transplant recipients with primary humoral nonresponse","volume":"100","author":"Westhoff","year":"2021","journal-title":"Kidney Int."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e13740","DOI":"10.1111\/tid.13740","article-title":"Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients","volume":"23","author":"Demir","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e150175","DOI":"10.1172\/JCI150175","article-title":"Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients","volume":"131","author":"Sattler","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1001\/jama.2021.4385","article-title":"Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients","volume":"325","author":"Boyarsky","year":"2021","journal-title":"JAMA"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1001\/jama.2021.7489","article-title":"Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients","volume":"325","author":"Boyarsky","year":"2021","journal-title":"JAMA"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"ofad150","DOI":"10.1093\/ofid\/ofad150","article-title":"Antibody Response After Third Vaccination with mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients with Different Levels of Immunosuppression (COVERALL-2)","volume":"10","author":"Griessbach","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1136\/gutjnl-2021-326755","article-title":"High antibody response in relation to immunosuppressive blood levels in liver transplant recipients after SARS-CoV-2 vaccination: An observational, cohort study","volume":"71","author":"Mulder","year":"2022","journal-title":"Gut"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e14585","DOI":"10.1111\/ctr.14585","article-title":"The type of SARS-CoV-2 vaccine influences serological response in kidney transplant recipients","volume":"36","author":"Correia","year":"2022","journal-title":"Clin. Transplant."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.6002\/ect.2021.0402","article-title":"Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients","volume":"19","author":"Erol","year":"2021","journal-title":"Exp. Clin. Transplant."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.1093\/cid\/ciac103","article-title":"Prospective evaluation of coronavirus disease 2019 (COVID-19) vaccine responses across a broad spectrum of immunocompromising conditions: The COVID-19 vaccination in the immunocompro-mised study (COVICS)","volume":"75","author":"Haidar","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000518631","article-title":"Impact of Shielding and First Dose of COVID-19 Vaccination in Kidney Transplant Recipients","volume":"146","author":"Middleton","year":"2021","journal-title":"Nephron"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Nazaruk, P., Monticolo, M., J\u0119drzejczak, A.M., Krata, N., Moszczuk, B., Sa\u0144ko-Resmer, J., Pilecki, T., Urbanowicz, A., Florczak, M., and P\u0105czek, L. (2021). Unexpectedly High Efficacy of SARS-CoV-2 BNT162b2 Vaccine in Liver versus Kidney Transplant Recipients\u2014Is It Related to Immunosuppression Only?. Vaccines, 9.","DOI":"10.3390\/vaccines9121454"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/S0140-6736(21)02096-1","article-title":"Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients","volume":"398","author":"Prendecki","year":"2021","journal-title":"Lancet"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e1391","DOI":"10.1002\/cti2.1391","article-title":"Humoral immunity against SARS-CoV-2 variants including omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccine","volume":"11","author":"Saharia","year":"2022","journal-title":"Clin. Transl. Immunol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"10321","DOI":"10.3389\/ti.2022.10321","article-title":"Antibody Response After a Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Liver Transplant Recipients","volume":"35","author":"Sakai","year":"2022","journal-title":"Transpl. Int."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.healun.2021.11.001","article-title":"SARS-CoV-2 anti\u2013spike antibodies after vaccination in pediatric heart transplantation: A first report","volume":"41","author":"Spinner","year":"2022","journal-title":"J. Heart Lung Transplant."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1002\/lt.26273","article-title":"Antibody Response to Severe Acute Respiratory Syndrome-Coronavirus-2 Messenger RNA Vaccines in Liver Transplant Recipients","volume":"27","author":"Strauss","year":"2021","journal-title":"Liver Transplant."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jhep.2022.02.015","article-title":"Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients","volume":"77","author":"Toniutto","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e13772","DOI":"10.1111\/tid.13772","article-title":"Humoral and cellular immune responses to the SARS-CoV-2 BNT162b2 vaccine among a cohort of solid organ transplant recipients and healthy controls","volume":"24","author":"Yanis","year":"2022","journal-title":"Transpl. Infect. Dis. Off. J. Transplant. Soc."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"5362","DOI":"10.1038\/s41467-022-33036-y","article-title":"Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: A randomized controlled trial","volume":"13","author":"Mrak","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1097\/TP.0000000000003856","article-title":"Low Immunization Rate in Kidney Transplant Recipients Also After Dose 2 of the BNT162b2 Vaccine: Continue to Keep Your Guard up!","volume":"105","author":"Midtvedt","year":"2021","journal-title":"Transplantation"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1111\/ajt.17091","article-title":"Fourth dose of the SARS-CoV-2 vaccine in kidney transplant recipients with previously impaired humoral antibody response","volume":"22","author":"Midtvedt","year":"2022","journal-title":"Am. J. Transplant."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1111\/ajt.16702","article-title":"Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients","volume":"21","author":"Miele","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1093\/ckj\/sfab125","article-title":"Factors associated with humoral response after BNT162b2 mRNA COVID-19 vaccination in kidney transplant patients","volume":"14","author":"Ducloux","year":"2021","journal-title":"Clin. Kidney J."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Li, Z., Liu, S., Li, F., Li, Y., Li, Y., Peng, P., Li, S., He, L., and Liu, T. (2022). Efficacy, immunogenicity and safety of COVID-19 vaccines in older adults: A systematic review and meta-analysis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.965971"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Pormohammad, A., Zarei, M., Ghorbani, S., Mohammadi, M., Razizadeh, M.H., Turner, D.L., and Turner, R.J. (2021). Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Vaccines, 9.","DOI":"10.2139\/ssrn.3812422"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/1\/72\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T05:11:45Z","timestamp":1768021905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/1\/72"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":143,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["vaccines14010072"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14010072","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]}}}